GLP1R and Alzheimer disease: Lixisenatide, another GLP-1R agonist, developed to treat type 2 diabetes, has been shown to have neuroprotective effects similar to liraglutide, including improved working memory, increased LTP, decreased Aβ deposition, and reduced inflammatory responses in an AD mouse model [140].